ESMO: Conjugate ups survival in advanced breast cancer

This article originally appeared here.
Share this content:
ESMO: Conjugate Ups Survival in Advanced Breast Cancer
ESMO: Conjugate Ups Survival in Advanced Breast Cancer

(HealthDay News) -- Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) have improved survival when treated with the antibody-drug conjugate trastuzumab emtansine (T-DM1), compared with lapatinib plus capecitabine, according to a study published online Oct. 1 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Society for Medical Oncology, held from Sept. 28 to Oct. 2 in Vienna.

Sunil Verma, M.D., from the Sunnybrook Odette Cancer Centre in Toronto, and colleagues randomly assigned 991 patients with advanced HER2-positive breast cancer to T-DM1 or lapatinib plus capecitabine. Patients had previously been treated with trastuzumab and a taxane.

The researchers found that the T-DM1 group had significantly longer median progression-free survival (9.6 versus 6.4 months; hazard ratio for progression or death from any cause, 0.65) and significantly longer median overall survival (30.9 versus 25.1 months; hazard ratio of death from any cause, 0.68). The T-DM1 group had lower rates of grade 3 or 4 adverse events (41 versus 57 percent). This group also had a significantly higher objective response rate and a longer median duration of response.

"In conclusion, our study shows that T-DM1 has therapeutic potential, across a heterogeneous population of patients, for the treatment of advanced, HER2-positive breast cancer that has progressed during or after treatment with trastuzumab and a taxane," Verma and colleagues conclude.

The study was funded by Hoffmann-La Roche/Genentech, the manufacturer of trastuzumab emtansine; several authors disclosed financial ties to pharmaceutical companies, including Hoffmann-La Roche/Genentech.

Full Text
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs